Table 1 General features of patients with dermatomyositis and health individuals

Age (years)

33.3 ± 7.6

35.8 ± 8.2

1.000

White ethnicity

36 (75.0)

32 (66.7)

0.501

Female gender

36 (75.0)

36 (75.0)

1.000

Age at disease onset (years)

30.9 ± 7.4

–

–

Duration: diagnosis - symptoms (months)

5.0 (2.3–8.5)

–

–

Disease duration (years)

1 (0–4)

–

–

 Articular involvement

14 (29.2)

–

–

 Pulmonary involvement

17 (35.4)

–

–

 Cutaneous involvement

48 (100.0)

–

–

  Gottron’s papules

47 (97.9)

–

–

  Heliotrope rash

40 (83.3)

–

–

  Facial rash

30 (62.5)

–

–

  Raynaud’ phenomenon

24 (50.0)

–

–

  “V-neck” sign

15 (31.3)

–

–

  Ulcers

10 (20.8)

–

–

  Vasculitis

10 (20.8)

–

–

  “Shawl” sign

8 (16.7)

–

–

  Calcinosis

0

–

–

MMT-8 (0–80)

78 (71–80)

HAQ (0.00–3.00)

0.36 (0.00–2.00)

–

–

Patient VAS (0–10 mm)

5 (1–6)

–

–

Physician VAS (0–10 mm)

4 (1–5)

–

–

Creatine phosphokinase (U/L)

200 (93–960)

100 (81–161)

Aldolase (U/L)

5.9 (4.1–12.9)

3.6 (3.1–4.3)

Lactic dehydrogenase (U/L)

412 (347–597)

323 (296–381)

Alanine aminotransferase (U/L)

25 (16–60)

17 (13–21)

Aspartate aminotransferase (U/L)

25 (19–52)

19 (16–22)

 Current use

34 (70.8)

–

–

 Current dose (mg/day)

20.0 (3.1–50.0)

–

–

 Cumulative dose^a (mg)

645 (90–2103)

–

–

 Cumulative dose^b (g)

15.5 (5.8–27.8)

–

–

Immunosupressive/imunmodulatory^c

–

 None

20 (41.7)

–

–

 One

11 (22.9)

–

–

 Two

17 (35.4)

–

–